« Back to Record
Citation APA

Wohl, D., Cheret, A., Brunetta, J., Mussini, C., Tebas, P., Sax, P. E. D. P., Cheng, A. K., Zhong, L., Callebaut, C., Das, M., Fordyce, M., Oka, S., Friborg, S., Villamejor, K., Huang, J., Guo, S., Liu, H., Wang, H., Miller, M., Margot, N., Clumeck, N., Clarke, A., Brinson, C., Stephens, J., Tashima, K., Arribas Lopez, J. R., & Rashbaum, B. (2016). A randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: Week 96 results. Journal of acquired immune deficiency syndromes, 72(1), 58-64. doi:10.1097/QAI.0000000000000940


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/236946

Wohl, D., Cheret, A., Brunetta, J., Mussini, C., Tebas, P., Sax, P. E. D. P., Cheng, A. K., Zhong, L., Callebaut, C., Das, M., Fordyce, M., Oka, S., Friborg, S., Villamejor, K., Huang, J., Guo, S., Liu, H., Wang, H., Miller, M., Margot, N., Clumeck, N., Clarke, A., Brinson, C., Stephens, J., Tashima, K., Arribas Lopez, J. R., & Rashbaum, B. (2016). A randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: Week 96 results. Journal of acquired immune deficiency syndromes, 72(1), 58-64. doi:10.1097/QAI.0000000000000940